Abstract
Twenty-one of 29 patients suffering from myasthenia gravis derived benefit from a short intensive course of adrenocorticotrophin (ACTH). The mean duration of benefit was approximately six months. The best results were obtained in patients with a short history of myasthenia. Transient deterioration during the course of injections was encountered in some cases but necessitated assisted respiration only in patients with severe generalized weakness before treatment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brunner N. G., Namba T., Grob D. Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy. Neurology. 1972 Jun;22(6):603–610. doi: 10.1212/wnl.22.6.603. [DOI] [PubMed] [Google Scholar]
- Cape C. A., Utterback R. A. Treatment of myasthenia gravis with adrenocorticotropic hormone (ACTH): massive short-term and maintenance treatment. J Neurol Neurosurg Psychiatry. 1969 Aug;32(4):290–296. doi: 10.1136/jnnp.32.4.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FREYDBERG L. D. The place of corticotropin in the treatment of myasthenia gravis. Ann Intern Med. 1960 Apr;52:806–818. doi: 10.7326/0003-4819-52-4-806. [DOI] [PubMed] [Google Scholar]
- GROB D., HARVEY A. M. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. Bull Johns Hopkins Hosp. 1952 Aug;91(2):124–136. [PubMed] [Google Scholar]
- Gibberd F. B., Navab F., Smith C. L. Treatment of ocular myasthenia with corticotrophin. J Neurol Neurosurg Psychiatry. 1971 Feb;34(1):11–13. doi: 10.1136/jnnp.34.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liversedge L. A. Short-term intensive corticotrophin treatment in myasthenia gravis. Proc R Soc Med. 1971 May;64(5):492–492. doi: 10.1177/003591577106400516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Namba T., Brunner N. G., Shapiro M. S., Grob D. Corticotropin therapy in myasthenia gravis: effects, indications, and limitations. Neurology. 1971 Oct;21(10):1008–1018. doi: 10.1212/wnl.21.10.1008. [DOI] [PubMed] [Google Scholar]
- Osserman K. E., Genkins G. Studies in myasthenia gravis. Short-term massive corticotropin therapy. JAMA. 1966 Nov 14;198(7):699–702. [PubMed] [Google Scholar]
- TORDA C., WOLFF H. G. Effects of administration of the adrenocorticotropic hormone on patients with myasthenia gravis. AMA Arch Neurol Psychiatry. 1951 Aug;66(2):163–170. doi: 10.1001/archneurpsyc.1951.02320080047004. [DOI] [PubMed] [Google Scholar]
- von Reis G., Liljestrand A., Matell G. Results with ACTH and spironolactone in severe cases of myasthenia gravis. Acta Neurol Scand Suppl. 1965;13(Pt 2):463–471. doi: 10.1111/j.1600-0404.1965.tb01915.x. [DOI] [PubMed] [Google Scholar]